Lunchtime ASX small cap wrap: who’s popping corks today

Link copied to
clipboard

Here are the key ASX small cap winners and losers at lunch Mon Oct 22:

The ASX Small Ords index was down 0.7 per cent or 19 points to 2686 by 12.45pm AEST.

GOING UP

Semen separator Memphasys (ASX:MEM) was swimming in the right direction this morning, moving ahead 41 per cent to 4.5c.

Memphasys is developing a membrane codenamed Felix that separates quick swimmers from flabby floaters to improve IVF procedures.

Today Memphasys told investors it had “entered a pivotal stage in the commercial development” of Felix, signing “the first of a number of leading international andrology and IVF clinics as partners to conduct invitro [or test tube] assessments”.

Under the deal, Memphasys will work with a Stockholm-based male infertility clinic ANOVA Karolinska “on the clinical validation of the Felix device”.

Memphasys is hoping for European regulatory approval in late 2019 which would allow for human trials.

Invigor (ASX:IVO) rose 33 per cent to 0.8c after confirming a deal that would see its technology used in China’s hugely popular WeChat social network.

Invigor more than doubled last month after it first announced a three-year deal with Winning Group, a partner of WeChat owner Tencent.

The stock later cooled to 0.5c before today’s recovery.

Invigor told investors the deal had now “become unconditional with both parties waiving the initial three-month pilot period and moving to live deployment of WeChat Pay in South-East Asia with the first significant customer introduced by Invigor”.

Newly renamed medical imaging service ImExHS (ASX:IME) gained 20 per cent to 3.7c after signing its biggest contract to date.

ImExHS changed its name from Omni Market Tide in August after raising $5.5 million at 2.5c per share to buy a business called Imaging and Healthcare Services.

ImExHS aims to be “one of the leaders of the Imaging Latin America market, offering flexible and scalable imaging solutions”.

Under today’s deal a columbian radiology group called Colsubsidio will convert from analog film to digital imaging.

The deal was valued at $2 million to $2.8 million over five years.

• Subscribe to our daily newsletter
• Bookmark this link forsmall cap news
• Join our small cap Facebook group
• Follow us on Facebook or Twitter

Manganese explorer Element 25 (ASX:E25) gained 25 per cent to 20c this morning after it started new drilling at its “Butcherbird” project in central Western Australia.

Butcherbird is said to be Australia’s biggest onshore manganese resource “comprising large tonnages of near-surface manganese oxide ore in seven deposits”.

Element 25 told investors today it had received heritage clearances from the Nyiyaparli native title claim group.

Drilling of 200 holes for a total of 7000m was now underday. Assays (or test results) are due on December and a revised resource estimate is planned for January.

Shares in explorer Bellevue Gold (ASX:BGL) climbed 22 per cent to 41c this morning on news it now has a war chest of more than 1 million ounces of high-grade gold.

Bellevue bumped up its “inferred” resource for its namesake project, located 400km northwest of Kalgoorlie in Western Australia, to 1.04 million ounces at 12.3 grams per tonne (g/t) gold.

Here are the best performing ASX small cap stocks at 12.15pm Mon Oct 22:

Swipe or scroll to reveal the full table. Click headings to sort

GOING DOWN

Jayex Healthcare (ASX:JHL) was down 28 per cent to 2.3c after confirming a July deal with Kiwi cannabis play MediCann NZ had been terminated.

Jayex had been planning to license remote dispensing terminals to MediCann ahead of expected changes in New Zealand law.

Here are the worst performing ASX small cap stocks at 12.15pm Mon Oct 22:

Swipe or scroll to reveal the full table. Click headings to sort

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

Hidden

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.